4.7 Article

Public Cord Blood Banks as a source of starting material for clinical grade HLA-homozygous induced pluripotent stem cells

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Hematology

GMP-grade CD34+ selection from HLA-homozygous licensed cord blood units and short-term expansion under European ATMP regulations

Stefanie Liedtke et al.

Summary: The study demonstrates the successful production of expanded CD34(+) cells from cryopreserved cord blood under European ATMP regulations, addressing the main obstacle of cell rejection by preselection of HLA-homozygous transplants. Approval was obtained for GMP-compliant production in March 2019, showcasing the clinical translation and implementation of a qualified manufacturing process.

VOX SANGUINIS (2021)

Article Cell & Tissue Engineering

Evaluation of the Spanish population coverage of a prospective HLA haplobank of induced pluripotent stem cells

Belen Alvarez-Palomo et al.

Summary: The background of generating iPSC haplobanks with homogeneous HLA haplotypes for allogeneic transplantation has been proposed as a cost-effective method. Initiatives have been made globally to create national and international iPSC haplobanks matching a significant portion of the population. This study in Spain demonstrates the feasibility of using cord blood units to establish an iPSC haplobank covering a substantial percentage of the population for future therapeutic strategies.

STEM CELL RESEARCH & THERAPY (2021)

Article Hematology

GMP-grade CD34(+) selection from HLA-homozygous licensed cord blood units and short-term expansion under European ATMP regulations

Stefanie Liedtke et al.

Summary: Based on a synergistic consortium, the cord blood bank in Dusseldorf selected HLA-homozygous donors, performed CD34(+) enrichment, short-term expansion of cells, and qualification of the resulting population for advanced therapy medicinal product (ATMP) use. Minimal criteria were established for CD34(+) cell qualification, with 10 cord blood units meeting the standards. Approval for GMP-compliant production was obtained in March 2019, demonstrating successful clinical translation and implementation of a qualified manufacturing process.

VOX SANGUINIS (2021)

Review Cell & Tissue Engineering

Pluripotent Stem Cell-Based Cell Therapy- Promise and Challenges

Shinya Yamanaka

CELL STEM CELL (2020)

Article Engineering, Biomedical

iPS cell-based therapy for Parkinson's disease: A Kyoto trial

Jun Takahashi

Regenerative Therapy (2020)

Review Immunology

Overview: an iPS cell stock at CiRA

Masafumi Umekage et al.

INFLAMMATION AND REGENERATION (2019)

Article Cell & Tissue Engineering

Recent progress of national banking project on homozygous HLA-typed induced pluripotent stem cells in South Korea

Yeri Alice Rim et al.

JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE (2018)

Article Cell & Tissue Engineering

Quality control guidelines for clinical-grade human induced pluripotent stem cell lines

Stephen Sullivan et al.

REGENERATIVE MEDICINE (2018)

Article Medicine, General & Internal

Autologous Induced Stem-Cell-Derived Retinal Cells for Macular Degeneration

M. Mandai et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Editorial Material Cell & Tissue Engineering

Development of a global network of induced pluripotent stem cell haplobanks

Ian Wilmut et al.

REGENERATIVE MEDICINE (2015)

Editorial Material Cell & Tissue Engineering

Generating an iPSC Bank for HLA-Matched Tissue Transplantation Based on Known Donor and Recipient HLA Types

Craig J. Taylor et al.

CELL STEM CELL (2012)